Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Acquisitions & Divestments: 2015-2023

Historic Change in Acquisitions & Divestments for Seres Therapeutics (MCRB) over the last 6 years, with Jun 2023 value amounting to $11.8 million.

  • Seres Therapeutics' Change in Acquisitions & Divestments fell 64.97% to $11.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $85.8 million, marking a year-over-year decrease of 47.94%. This contributed to the annual value of $23.0 million for FY2023, which is 83.64% down from last year.
  • Latest data reveals that Seres Therapeutics reported Change in Acquisitions & Divestments of $11.8 million as of Q2 2023, which was up 4.60% from $11.2 million recorded in Q1 2023.
  • Seres Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $54.8 million for Q2 2021, and its period low was $2.5 million during Q3 2020.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $37.5 million (2022), whereas its average is $33.3 million.
  • As far as peak fluctuations go, Seres Therapeutics' Change in Acquisitions & Divestments soared by 1,653.98% in 2021, and later plummeted by 74.52% in 2023.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Change in Acquisitions & Divestments stood at $16.9 million in 2019, then climbed by 1.68% to $17.2 million in 2020, then soared by 154.03% to $43.6 million in 2021, then tumbled by 50.81% to $21.5 million in 2022, then plummeted by 64.97% to $11.8 million in 2023.
  • Its Change in Acquisitions & Divestments was $11.8 million in Q2 2023, compared to $11.2 million in Q1 2023 and $21.5 million in Q4 2022.